¿Quién es inmune? ¿Inmunidad de rebaño o vacuna? | 30 ABR 20
Lo que los responsables sanitarios deben saber sobre la inmunidad protectora COVID-19
No hay certeza en cuanto a los correlatos inmunológicos de la protección antiviral o la proporción de la población que debe alcanzarlos, lo que hace imposible identificar un punto cuando se ha alcanzado este nivel de inmunidad.
Studdert DM Hall MA. Disease control, civil liberties, and mass testing—calibrating restrictions during the COVID-19 pandemic. N Engl J Med. 2020; (published online April) DOI:10.1056/NEJMp2007637
Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020; 64: e00399-e00420
Amanat F Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020; 52: 583-589
Thanh Le T Andreadakis Z Kumar A et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; (published online April 9.) DOI:10.1038/d41573-020-00073-5
Adams ER Anand R Andersson M et al. Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. bioRxiv. 2020; (published online April 20.) (preprint) https://doi.org/10.1101/2020.04.15.20066407
Plotkin SA. Vaccination against the major infectious diseases. CR Acad Sci III. 1999; 322: 943-951
Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001; 20: 63-75
Tan W Lu Y Zhang J et al. Viral kinetics and antibody responses in patients with COVID-1 MedRxiv. 2020; (published online March 26.) (preprint) https://doi.org/10.1101/2020.03.24.20042382
Stanley DA Honko AN Asiedu C et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014; 20: 1126-1129
Li CK Wu H Yan H et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008